Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 25 and up

Comparing the effects of LSD, psilocybin, and DMT on consciousness in healthy individuals

Official title: Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)

Run by University Hospital, Basel, Switzerland · NCT06899334 · Data updated 2026-11-12

This study is testing how three different psychedelics—LSD, psilocybin, and DMT—affect people's consciousness to see how they compare in healthy individuals.

More Healthy Aging trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages25 Years and up
SexAll
Enrollment24 (estimated)
SponsorUniversity Hospital, Basel, Switzerland
Academic / other
Locations1 site (Basel)
StatusRecruiting
StartedApril 1, 2025
Main results expectedAugust 1, 2026
Study endsAugust 1, 2026
Registry record updatedMarch 27, 2025
Trial IDNCT06899334 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are healthy individuals aged 18-65 with a good understanding of the German language and no history of major psychiatric disorders.

Probably not a fit

Patients with chronic medical conditions or a history of psychiatric disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the effects of three psychedelics—LSD, psilocybin, and DMT—on consciousness in healthy participants. By administering equivalent doses of each substance while standardizing the duration of effects with ketanserin, the researchers will evaluate the qualitative similarities and differences in the peak experiences induced by these hallucinogens. The study is designed to ensure blinding and control for pharmacokinetic differences, making it a unique direct comparison of these substances. Participants will undergo a series of assessments to measure the acute and subacute effects of each psychedelic.

Why it matters

Potential benefit: If successful, this study could enhance our understanding of psychedelics and their therapeutic potential for treating psychiatric disorders.

How similar studies have gone: While there have been studies on LSD and psilocybin, this direct comparison with DMT is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Good understanding of the German language
2. Understanding of procedures and risks associated with the study
3. Willing to adhere to the protocol and signing of the consent form
4. Willing to refrain from the consumption of illicit psychoactive substances during the study
5. Willing not to operate heavy machinery within 48 h after administration of a study substance
6. Willing to use effective birth control throughout study participation
7. Body mass index 17 - 34.9 kg/m2

Exclusion Criteria:

1. Relevant chronic or acute medical condition
2. Current or previous major psychiatric disorder (e.g. psychotic disorder)
3. Psychotic disorder or bipolar disorder in first-degree relatives
4. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg)
5. Bradycardia (\< 45 bpm)
6. Prolonged QTc interval (males: \>450 ms, females: \>470 ms)
7. AV block II° (Mobitz type and Webckebach type) and III°
8. Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months
9. Pregnancy or current breastfeeding
10. Participation in another clinical trial (currently or within the last 30 days)
11. Use of medication that may interfere with the effects of the study medication
12. Tobacco smoking (\>10 cigarettes/day)
13. Excessive consumption of alcoholic beverages (\>15 drinks/week)

Where it's running

  • University Hospital
    Basel, Switzerland
    Recruiting

Study contacts

  • Principal investigator: Matthias E Liechti, Prof. Dr. MD — University Hospital, Basel, Switzerland
  • Study coordinator: Matthias E Liechti, Prof. Dr. MD
  • Email: matthias.liechti@usb.ch
  • Phone: 61 328 68 68

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.